<DOC>
	<DOCNO>NCT01982630</DOCNO>
	<brief_summary>This study evaluate safety , efficacy , pharmacokinetics MK-8521 give daily compare placebo another diabetes drug participant Type 2 diabetes mellitus ( T2DM ) . This study modify protocol amendment 2-part trial test safety tolerability MK-8521 high dos compare MK-8521 pharmacokinetics participant T2DM healthy participant . An additional cohort T2DM participant cohort non-diabetic obese participant add .</brief_summary>
	<brief_title>Study Safety Efficacy MK-8521 Compared Placebo Diabetes Drug Participants With Type 2 Diabetes Mellitus ( MK-8521-003 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Male , female nonchildbearing potential Type 2 diabetes mellitus ( Parts I II ) nondiabetic ( Part II ) Body mass index ( BMI ) : 27 &gt; = &lt; = 40 kg/m^2 A1C ( average blood sugar past 2 3 month ) value &gt; = 7.0 &lt; = 11.0 % ( Part I ) &gt; = 6.5 &lt; = 11.0 % ( Part II ) time screen ( T2DM participant ) A1C value &lt; 5.7 time screening ( nondiabetic subject Part II ) On stable dose metformin ( &gt; =1000 mg total daily dose ) least 12 week time screen ( T2DM participant ) Mentally legally incapacitate History clinically significant psychiatric disorder last 5 year . Participants situational depression may enrol trial discretion Investigator History Type 1 diabetes mellitus history ketoacidosis History clinically significant gastrointestinal , hematological , hepatic , immunological , renal , respiratory , genitourinary major neurological abnormality diseases History cardiovascular disease cardiac conduction disorder History cancer ( malignancy ) . Exceptions may include adequately treated nonmelanomatous skin carcinoma carcinoma situ cervix malignancy successfully treat &gt; =10 year prior prescreening visit History proliferative diabetic retinopathy maculopathy Clinically significant diabetic autonomic neuropathy QTc interval &gt; = 470 msec ( male ) &gt; = 480 msec ( female ) Clinical significant electrocardiogram ( ECG ) abnormality Positive hepatitis B surface antigen , hepatitis C antibody , human immunodeficiency virus ( HIV ) On weight loss program weightstable ( weight stable define history &lt; 5 % change body weight last 3 month On weight loss medication undergone bariatric surgery Major surgery , donate lose 1 unit blood ( approximately 500 mL ) within 4 week prior pretrial ( screen ) visit Participated another investigational trial within 4 week prior pretrial ( screen ) visit History acute chronic pancreatitis etiology Mean value triplicate semirecumbent systolic blood pressure &gt; 160 mm Hg and/or diastolic blood pressure &gt; 90 mm Hg ( least 10minute seated rest ) blood pressure consider unlikely limit Day1 ( Randomization ) initiation adjustment antihypertensive medication Event severe hypoglycemia seizure loss consciousness past 12 month Treated antihyperglycemic agent metformin within last 12 week Previous exposure glucagonlike peptide1 ( GLP1 ) receptor agonist ( e.g . Byetta™ , Victoza™ investigational agent )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>